[{"orgOrder":0,"company":"Urovant Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Urovant Sciences Announces Positive Topline Results of Phase 2a Trial of its Potential Novel Gene Therapy, URO-902","therapeuticArea":"Urology","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Hmaxi-K","moa":"","url1":"","url2":"","graph1":"Urology","graph2":"Phase II","graph3":"Urovant Sciences","amount2":0,"therapeuticAreaNew":"Urology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Urology","productSubType":"","amount2New":0,"dosageForm":"Intradetrusor Injection","sponsorNew":"Urovant Sciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Urovant Sciences \/ Not Applicable"},{"orgOrder":0,"company":"Urovant Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Urovant Sciences to Present Interim Data from Phase 2a Study of Potential Novel Gene Therapy, URO-902, and New Analyses of Data from Phase 3 EMPOWUR Extension Trial of GEMTESA\u00ae (vibegron) 75 mg at 2022 American Urological Association Annual Meeting","therapeuticArea":"Urology","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"hMaxi-K","moa":"","url1":"","url2":"","graph1":"Urology","graph2":"Phase II","graph3":"Urovant Sciences","amount2":0,"therapeuticAreaNew":"Urology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Urology","productSubType":"","amount2New":0,"dosageForm":"Intradetrusor Injection","sponsorNew":"Urovant Sciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Urovant Sciences \/ Not Applicable"},{"orgOrder":0,"company":"Urovant Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Urovant Sciences\u00ae Presents Interim Data from Phase 2a Study of Investigational Novel Gene Therapy, URO-902, Supporting Safety, Tolerability, and Efficacy Endpoints at 2022 American Urological Association Meeting","therapeuticArea":"Urology","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Hmaxi-K","moa":"","url1":"","url2":"","graph1":"Urology","graph2":"Phase II","graph3":"Urovant Sciences","amount2":0,"therapeuticAreaNew":"Urology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Urology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Urovant Sciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Urovant Sciences \/ Not Applicable"}]
Find Clinical Drug Pipeline Developments & Deals for Hmaxi-K
Details :
Interim 12-week analysis from an ongoing Phase 2a trial of an investigational novel gene therapy product URO-902 (hMaxi-K), showed clinically relevant improvement in the common symptoms of overactive bladder (OAB) compared to placebo.
Details :
Interim 12-week analysis from a Phase 2a trial of the potential gene therapy, URO-902, in women with overactive bladder and urge urinary incontinence will be featured in a late-breaker presentation during plenary session.
Details :
URO-902 showed a clinically meaningful and statistically significant effect on a number of relevant outcome measures in OAB including number of micturitions, urgency episodes, and quality of life indicators compared to placebo, 12 weeks post-administrati...
Market Place
Reset All
